This is a repository copy of *Chronic urticaria in the real-life clinical practice setting in the UK: results from the non-interventional multicentre AWARE study.*

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/159431/

Version: Accepted Version

**Article:**
Savic, S orcid.org/0000-0001-7910-0554, Leeman, L, El-Shanawany, T et al. (11 more authors) (2020) Chronic urticaria in the real-life clinical practice setting in the UK: results from the non-interventional multicentre AWARE study. Clinical and Experimental Dermatology. ISSN 0307-6938

https://doi.org/10.1111/ced.14230

This article is protected by copyright. All rights reserved. This is the peer reviewed version of the following article: Savic, S., Leeman, L., El‐Shanawany, T., Ellis, R., Gach, J., Marinho, S., Wahie, S., Sargur, R., Bewley, A., Nakonechna, A., Randall, R., Fragkas, N., Somenzi, O. and Marsland, A. (2020), Chronic urticaria in the real-life clinical practice setting in the UK: results from the non-interventional multicentre AWARE study. Clin Exp Dermatol. Accepted Author Manuscript., which has been published in final form at https://doi.org/10.1111/ced.14230. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Chronic urticaria in the real-life clinical practice setting in the UK: results from the non-interventional multicentre AWARE study

S. Savic,1 L. Leeman,2 T. El-Shanawany,3 R. Ellis,4 J.E. Gach,5 S. Marinho,6 S. Wahie,7 R. Sargur,8 A.P. Bewley,9 A. Nakonechna,10 R. Randall,11 N. Fragkas,11 O. Somenzi11 and A. Marsland12

1St James’s University Hospital, Leeds, UK; 2University Hospitals Plymouth NHS Trust, Plymouth, UK; 3University Hospital of Wales, Cardiff, UK; 4James Cook University Hospital, Middlesbrough, UK; 5University Hospitals Coventry and Warwickshire, Coventry, UK; 6Wythenshawe Hospital, Manchester University Foundation Trust and University of Manchester, Manchester, UK; 7University Hospital of North Durham, Durham, UK; 8Sheffield Teaching Hospitals, Sheffield, UK; 9Barts Health NHS Trust, London, UK; 10Sheffield Teaching Hospitals, Sheffield, UK and University of Liverpool, Liverpool, UK; 11Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK; 12Salford Royal Hospital, Salford, UK and University of Manchester, Manchester, UK

Correspondence: Alexander Marsland

Email: alexander.marsland@manchester.ac.uk

Keywords: angioedema, chronic spontaneous urticaria, healthcare use, urticaria

Disclosures: SS has received educational support and speaker fees and/or advisory fees from CSL, Novartis Takeda, Grifols and Sobi, as well as research grants from CSL and Sobi. LL has received educational support and speaker fees and/or advisory fees from CSL, Novartis and Takeda. TE-S has received educational support, research support, speaker fees and/or advisory fees from Allergy Therapeutics, Biotest, CSL, LFB, Mylan, Pharming, Shire and Novartis. RE is a director and shareholder of AMLo Biosciences and has received consultation fees from AbbVie. JEG received educational support from Novartis to attend dermatology meetings inclusive of registration fees, accommodation and travel expenses. SM received educational support and speaker fees from Allergy Therapeutics, Thermo Fisher, Mylan and Novartis. SW has received sponsorship to attend...
dermatology conferences, with travel, accommodation and meals paid for, from Janssen, AbbVie, Novartis and Almirall. RS has received consultation fees, speaker fees and assistance with conference travel from Novartis, CSL, Pharming and Shire. APB has received consultation fees from AbbVie, Almirall, Janssen, Leo Pharma, Novartis, Lilly, Galderma and UCB. AN has received speaker fees and/or advisory fees from Thermo Fisher and Novartis, and assistance with conference attendance from Allergy Therapeutics and ALK-Abelló. RR, NF and OS are employees of Novartis Pharmaceuticals UK Ltd. AM has received consultation fees, speaker fees and assistance with conference travel from Almirall, Galderma, MEDA, Novartis, Roche and Sanofi in the past 5 years.

**Running head:** CU in the clinical practice setting in the UK
Abstract

Background. Chronic urticaria (CU) is a skin condition characterised by repeated occurrence of itchy wheals and/or angioedema for >6 weeks.

Aim. To provide data demonstrating the real-life burden of CU in the UK.

Methods. This UK subset of the worldwide, prospective, non-interventional AWARE study included patients aged 18–75 years diagnosed with H1-antihistamine (H1-AH)-refractory chronic spontaneous urticaria (CSU) for >2 months. Baseline characteristics, disease activity, treatments, comorbidities and healthcare resource use were documented. Quality of life, work productivity and activity impairment were assessed.

Results. Baseline analysis included 252 UK patients. Mean age and body mass index were 45.0 years and 29.0 kg/m², respectively. Most patients were female (77.8%) and had moderate/severe disease activity (mean Urticaria Activity Score over 7 days, 18.4) and a ‘spontaneous’ component to their CU (73.4% CSU; 24.6% CSU and chronic inducible urticaria). Common comorbidities included depression/anxiety (24.6%), asthma (23.8%) and allergic rhinitis (12.7%). A previous treatment was recorded for 57.9% of patients. Mean Dermatology Life Quality Index score was 9.5 and patients reported impairments in work productivity and activity. Healthcare resource use was high. Severity of CSU was associated with gender, obesity, anxiety and diagnosis. Only 28.5% of patients completed all nine study visits, limiting analysis of long-term treatment patterns and disease impact.

Conclusions. Adult H1-AH-refractory CU patients in the UK reported high rates of healthcare resource use and impairment in quality of life, work productivity and activity at baseline. The differing structures of UK healthcare may explain the high study discontinuation rates versus other countries.
Introduction

Chronic urticaria (CU) is a group of skin conditions that include chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) characterised by the recurrence of itchy wheals and/or angioedema for >6 weeks, with (CIndU) or without (CSU) the need for provoking stimuli.\textsuperscript{1-4} The estimated worldwide prevalence of CU is up to 1\% in the general population.\textsuperscript{4} However, direct information on CSU prevalence in the general population is not available due to difficulties in classification, identification and diagnosis of CU.\textsuperscript{2}

The ASSURE study found considerable delay in diagnosis and specialist referral and inadequate knowledge about CSU among medical staff in primary and secondary care.\textsuperscript{4} Incorrect and ineffective treatment patterns were identified, and poor compliance with guidelines resulted in unnecessary investigations and delayed treatments, highlighting many unmet needs in CSU.\textsuperscript{4} Moreover, data on real-life consequences of CU are still limited and little is known about the disease burden, healthcare resource use and socioeconomic impact on H1-antihistamine (H1-AH)-refractory CU patients treated by general practitioners.

The non-interventional AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) study collected data from a representative sample of CU patients across the world to document real-life treatment scenarios, burden of disease and use of clinical resources in patients with H1-AH-refractory CU.\textsuperscript{5-9} Our paper reports the UK-specific analysis of baseline demographics of patients with CU, disease characteristics in CSU patients refractory to H1-AHs, as well as healthcare use and impairment in quality of life (QoL), work productivity and activity.

Methods

UK data were collected as part of the non-interventional, multinational, umbrella-design AWARE study. Patients were enrolled between September 2014 and August 2017 from specialised secondary/tertiary dermatology and/or immunology centres across the UK (Salford, Poole, London, Manchester, Chester, Sheffield, Coventry and Warwickshire, Durham, Leeds, Cardiff, Plymouth, Kent and Canterbury, Lewisham, Belfast, Hull, Leicester, Middlesbrough and Liverpool). Centres were selected according to whether they routinely treat CU patients refractory to at least one H1-AH.
Study objectives

The overall primary objective of the worldwide AWARE study, designed before widespread use and approval of omalizumab, was correlation of patient-reported outcomes with treatment options in patients with H1-AH-refractory CU. The study was designed to give a 2-year clinical ‘snapshot’ of patients with CU.

This analysis reports baseline demographics of patients with CU in the UK and analysis of disease characteristics including disease activity/progression over 24 months in patients completing the study.

Study population

CU patients refractory to recommended H1-AH therapy were eligible for enrolment. Inclusion criteria included age ≥18 years, medically confirmed diagnosis of CU present for >2 months and refractory to treatment with at least one H1-AH (licensed dose). Patients were informed about the study and provided written consent.

Study design

Patients were observed for 2 years, with eight follow-up visits in quarterly intervals after the baseline visit (Visit 1) (Fig. 1). Variables assessed included demographic data (including height, weight, age and gender), disease activity, current angioedema or angioedema since last visit (skin examination and patient report), comorbidities, current pharmacological treatment, satisfaction with current treatment (visual analogue scale [VAS]) and health-related QoL. Patients also reported how frequently they had missed work (sick leave) and visited additional healthcare resources (including emergency services, hospitalisations, general practitioners, specialised urticaria centres, dermatologists, allergists, ear, nose and throat specialists, dentists and alternative practitioners) since their urticaria symptoms first appeared.

Patient-reported outcomes

Four patient-reported outcomes (Dermatology Life Quality Index [DLQI],\textsuperscript{10} Urticaria Activity Score over 7 days [UAS7],\textsuperscript{11} EuroQol five-dimensions instrument\textsuperscript{12} and Work Productivity and
Activity Impairment questionnaire [WPAI][13] were offered and used to assess disease control and impact of CSU on patients’ QoL.

**Statistical analysis**

Descriptive analyses were performed to gain an understanding of the qualitative and quantitative nature of the data collected and characteristics of the sample studied. Continuous variables were reported as mean (and standard deviation) or median, minimum and maximum, where appropriate. Categorical variables were reported as counts and proportion of the total study population, where appropriate.

Multivariate analysis was performed using a model based on backward selection. Dependent variables were UAS7 or DLQI. All respective variables with ≤10% missing values and a frequency of ≥5% were used.

**Results**

**Study population**

A total of 265 patients were registered from 21 centres across the UK – 252 patients with CU met all study criteria, of whom 126 were enrolled in a dermatology centre and 126 were enrolled in an immunology and allergy centre. The majority of CU patients included in the study were diagnosed with CSU (n=185; 73.4% [Table 1]). The number of patients with any CSU was 247. Overall, 28.5% of all study patients completed the study. Reasons for discontinuation were lost to follow-up (72.1%), spontaneous remission of CU (20.3%), withdrawal of informed consent (6.4%), relocation (0.6%) and death (0.6%). When compared to patients who discontinued the study, patients who completed the study were older (mean age [SD] 50.02 years [15.01]) vs 43.6 years [15.08]; \( p=0.005 \) and tended to have more comorbidities such as atopic dermatitis (15.4% vs 5%; \( p=0.096 \)) and food allergy (9.6% vs 3%; \( p=0.0375 \)). Patients who remained in the study were also more likely to be on therapy, including “any treatment” (75% vs 53.5%; \( p=0.0051 \)), omalizumab (7.7% vs 0.5%; \( p=0.0009 \)) and ciclosporin (23.1% vs 7%; \( p=0.0007 \)). Patient numbers per visit are shown in Fig. 1.
Baseline demographics and disease characteristics

Baseline demographics and disease characteristics for the overall population and according to enrolment centre specialty are presented in Table 1. Overall, 57.9% of patients reported using treatments for CU. Depression/anxiety disorder (24.6%), asthma (23.8%) and allergic rhinitis (12.7%) were the most frequently reported comorbidities. Asthma (p=0.0078), allergic rhinitis (p=0.0007), other type of eczema (p=0.0006), food allergy (p=0.0055) and obesity (p=0.0098) were more frequently reported in patients enrolled at immunology/allergy centres. Patients from immunology/allergy centres also reported more angioedema (p=0.0004) and angioedema of greater severity (p=0.0099) compared to patients enrolled at dermatology centres.

Occurrence of itchy wheals and angioedema

At baseline, wheals on presentation or in the preceding 6 months were reported in 79.4% of patients (Table 1). Individual lesions were reported as lasting for >24 hours for 40.7% of patients. Skin biopsy to look for evidence of vasculitis had been performed in 10.4% of cases. The frequency of flare-ups with wheals declined during the study period from 73.5% (Visit 5) to 69.0% (Visit 9).

Angioedema was reported by 55.9% of patients in the 6 months preceding the initial study visit, with 88.2% of these cases occurring in association with wheals, and 77.3% of these patients reporting moderate or severe angioedema intensity. According to disease activity (UAS7 0–15, 16–27 and 28–42), average duration of angioedema (hours) at Visit 1 was 69.7 (range 5.0–72.0), 34.3 (range 4.0–48.0) and 34.0 (range 8.5–48.0), respectively. Occurrence of reported angioedema decreased to 47.6% (Visit 5) and 27.3% (Visit 9) over the study period.

Patient-reported outcomes

At baseline, mean UAS7 was 18.4, with 42.9%, 26.7% and 30.4% of patients reporting mild (UAS7 0–15), moderate (UAS7 16–27) and severe (UAS7 28–42) disease severity, respectively. Mean DLQI score was 9.5, with 41.8% of patients reporting a large or extremely large impact on QoL (DLQI total score ≥11). Overall mean value of the VAS, assessing satisfaction with therapy, was 6.6 (VAS range: 0 [not at all satisfied] to 10 [very satisfied]). Percentage of work impairment as assessed by the WPAI was 28.8%.
Mean total activity impairment was 34.1%, and 32.9% of patients reported at least one sick leave due to urticaria since time of diagnosis; cumulatively, patients were sick for an average of 17.5 weeks. Changes in DLQI, VAS, WPAI and total activity impairment over the study period are presented in Table 2.

**Use of medical and clinical resources**

Use of medical and clinical resources at baseline and over the study period are presented in Table 3. 33.8% of patients visited an emergency physician or accident and emergency (A&E) department, of whom 68.2% reported angioedema. 12.3% were hospitalised for CU symptoms at least once before enrolment into the study. 84.1% had visited a general practitioner, 41.0% had visited an additional dermatologist or allergist and 25.1% had visited a specialised urticaria centre (Table 3). The average number of visits was 7–13 before study enrolment.

**Multivariate analysis**

Severity of CSU (UAS7 score) was associated with gender (female), obesity, anxiety disorder and diagnosis (for both CSU and CIndU). Analysis revealed significant positive correlations between UAS7 and gender (female) (p=0.0014). A positive correlation was observed for anxiety disorder, but this was not significant. There was a significant negative correlation between UAS7 and obesity (p=0.0166) and UAS7 and diagnosis for both CSU and CIndU (p=0.0245).

QoL (DLQI score) was associated with gender (female), age, obesity, anxiety disorder and diagnosis (for both CSU and CIndU). Significant positive correlations were observed for gender (female) (p=0.0056) and anxiety disorder (p=0.0054). A negative correlation was observed for age (p=0.008). A trend for negative correlation of DLQI score for obesity was reported (p=0.0690).

**Discussion**

We present baseline disease characteristics and demographics from a study of 265 H1-AH-refractory CU patients referred to specialised urticaria centres in the UK. Notably, only 28.5% of patients completed all nine visits. This may be due to a large number of patients achieving remission and the nature of the UK healthcare system where availability and access to specialist secondary and tertiary care vary between regions, with patients largely managed within the primary care system. As such, the high rate of study discontinuation may be largely due to patients...
returning to primary care management following resolution of initial symptoms and associated problems. This is consistent with the most frequently stated reasons for early study discontinuation (‘lost to follow-up’ and ‘spontaneous remission of CU’), as well as the value of adequate knowledge of the importance of adherence to treatment guidelines in the management of CU, which would have been high in these specialised secondary and tertiary centres.

The baseline characteristics reported in this study of UK patients are generally comparable with previously published literature, with the majority of patients being female, and similar reported mean age and body mass index. Psychiatric comorbidities (depression/anxiety) were the most frequently reported comorbidities; this was unsurprising given the large psychological impact of CU. In the UK, a primary care physician may have a choice of referring a patient with suspected urticaria to an allergist/immunologist or a dermatologist. Differences were observed depending on the specialty of the recruiting physician (allergy/immunology vs dermatology), with patients at an allergy centre reporting a greater prevalence and intensity of angioedema, as well as a higher number of comorbidities. Prior medication history was relatively similar, although patients enrolled at a dermatology centre were more likely to have received sedative H1-AH. These findings partly reflect referral criteria/patterns in the UK since, for example, patients with angioedema are typically referred to immunology centres in the first instance. Coexistence of these two conditions in the same patient might imply to a referring physician that the urticaria may be allergic in origin and subsequently be more frequently referred to an allergist/immunologist.

Previous publications report that CU is associated with poor QoL, increased healthcare use and increased absenteeism, presenteeism and work impairment. Consistent with this, a moderate impact (at least) of CU on QoL was reported, and impairments in work productivity and activity were reported in almost one third of patients. Angioedema was reported in >50% of patients, with >75% reporting at least moderate disease intensity, which is likely to have an additional negative impact on QoL, work productivity and activity. Furthermore, presence of wheals for >24 hours was reported in approximately 40% of patients. While these results may be due to patients over-reporting the presence of symptoms, it is also indicative of the impact of disease patients with CU feel. The economic burden of CU in the UK was also evident, with a third of patients reporting A&E department attendance since symptom start, and a higher rate of A&E attendance in patients reporting angioedema. CSU should almost never require A&E attendance or admission since it is not life-threatening, and A&E attendance rates may reflect the difficulty some patients experience...
in seeing their primary care physician urgently and a general lack of understanding of the condition, highlighting the need to ensure patients are managed appropriately to optimise their QoL and reduce the socioeconomic burden of CU.

The correlation between QoL and age (negative) and QoL and anxiety disorder (positive) provides an insight into the impact of CSU on younger patients and reflects the social, physical, emotional and psychological status. Although body mass index has been suggested as a risk factor for CSU, we found a significant negative correlation between disease severity and obesity. This is consistent with results in a French cohort reporting lack of association between obesity and severe CSU. Additional research is required to investigate any causal relationship between obesity and CSU.

One limitation is the potential for selection bias as patients were recruited from specialised urticaria centres, biasing recruitment towards patients with more severe CU. Additionally, high rates of study discontinuation limit analysis of disease activity, long-term treatment patterns and disease impact. Finally, patients may over-report certain symptoms based on current feelings of discomfort or misunderstanding of how to quantify the presence of symptoms. Further studies exploring management of patients within the UK healthcare system may provide further insight.

Conclusion

These data highlight the disease burden and impact of H1-AH-refractory CU on patients treated in specialised centres in the UK. Patients have impaired health-related QoL, high usage of healthcare resources and impaired work productivity. Further investigation into management of CU patients outside secondary and tertiary care is needed to ensure patients are managed appropriately to optimise their QoL and reduce the socioeconomic burden of CU.

What is already known about this topic?

- CU remains uncontrolled in approximately half of patients, despite the use of licensed doses of H1-AHs
- Previous studies have established unmet needs in the treatment and management of patients with H1-AH-refractory CU, including delays in diagnosis and specialist referral,
inadequate knowledge among medical staff, incorrect treatment patterns and poor compliance with guidelines and best practices

What does this study add?

- The study demonstrates the significant impairments in QoL and work productivity and high healthcare resource use in many patients with H1-AH-refractory CU in the UK
- These findings suggest that patients presenting with both urticaria and angioedema were more frequently referred to an allergist/immunologist, rather than a dermatologist
- The data reflect clinical practice for CU in the UK and demonstrate the disease burden and unmet needs of patients with CU, highlighting the need to ensure appropriate management to optimise patient QoL and reduce the socioeconomic burden of CU in the UK

Acknowledgements

The authors would like to acknowledge Suzannah August, Richard Azurdia, Lisa Devlin, Eva Domarne, Emilia Duarte-Williamson, Kevin McKenna, Anna Chapman, John Lear, Pavels Gordins and Karen Harman for their contributions to the generation of data.

Medical writing assistance and editorial support, funded by Novartis Pharmaceuticals UK Ltd, was provided by Mei Lye and Rebecca Fletcher from Complete HealthVizion. The study was sponsored by Novartis Pharmaceuticals UK Ltd.
References

1. Zuberbier T, Aberer W, Asero R et al. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy 2018; 73: 1393–414.

2. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011; 66: 317–30.

3. Sánchez-Borges M, Asero R, Anzotegui IJ et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5: 125–47.

4. Maurer M, Abuzakouk M, Bérard F et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005–16.

5. Maurer M, Houghton K, Costa C et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J 2018; 11: 32.

6. Koti I, Weller K, Makris M et al. Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. Dermatology 2013; 226: 371–9.

7. Maurer M, Raap U, Staubach P et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019; 49: 655–62.

8. Thomsen SF, Pritzier EC, Anderson CD et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol 2017; 31: 1048–55.
Maurer M, Staubach P, Raap U et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017; 47: 684–92.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994; 19: 210–6.

Mlynek A, Zalewska-Janowska A, Martus P et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777–80.

Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis 2012; 78: 155–9.

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–65.

Costa AC, Rosmaninho I, Guilherme A et al. Chronic urticaria in the real-life clinical practice setting in Portugal: baseline results from the non-interventional multicentre AWARE study. Acta Med Port 2019; 32: 133–40.

Lapi F, Cassano N, Pegoraro V et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol 2016; 174: 996–1004.

Mendelson MH, Bernstein JA, Gabriel S et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. Journal of Dermatological Treatment 2017; 28: 229–36.

O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. British Journal of Dermatology 1997; 136: 197–201.

Vietri J, Tian H, Gabriel S et al. Economic burden of chronic spontaneous urticaria and psoriasis: patients perspective from Europe. Value in Health 2015; 18: A424–A5.
19 Shalom G, Magen E, Babaev M et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients. *J Eur Acad Dermatol Venereol* 2018; 32: 276–81.

20 Soria A, Du-Thanh A, Amsler E et al. Obesity is not associated with severe chronic urticaria in a French cohort. *J Eur Acad Dermatol Venereol* 2018; 32: e247–e9.
Table 1  Baseline demographics and disease characteristics, both overall and according to centre of specialty enrolment

|                                | Allergy centre (n=126) | Dermatology centre (n=126) | All patients (N=252) |
|--------------------------------|------------------------|----------------------------|----------------------|
| Age (years), mean (SD)         | 43.8 (14.2)            | 46.1 (16.3)                | 45.0 (15.3)          |
| Sex, n (%)                     |                        |                            |                      |
| Male                           | 25 (19.8)              | 31 (24.6)                  | 56 (22.2)            |
| Female                         | 101 (80.2)             | 95 (75.4)                  | 196 (77.8)           |
| Diagnosis, n (%)               |                        |                            |                      |
| CSU                            | 90 (71.4)              | 95 (75.4)                  | 185 (73.4)           |
| CIndU                          | 1 (0.8)                | 4 (3.2)                    | 5 (2.0)              |
| CSU + CIndU                    | 35 (27.8)              | 27 (21.4)                  | 62 (24.6)            |
| Duration of disease (years), mean (SD) | 4.8 (7.1)              | 5.0 (7.9)                  | 4.9 (7.5)            |
| Family-related history of urticaria, n (%) | 11 (8.7)               | 6 (4.9)                    | 17 (6.8)             |
| Systolic blood pressure (mmHG), mean (SD) | 131.3 (16.0)           | 127.5 (15.8)               | 129.6 (16.0)         |
| Diastolic blood pressure (mmHG), mean (SD) | **81.2 (10.9)**        | **77.3 (11.0)**            | 79.5 (11.1)          |
| Body mass index (kg/m²), mean (SD) | **30.1 (6.4)**         | **27.6 (5.0)**             | 29.0 (5.9)           |
| Prior medications, n (%)       |                        |                            |                      |
| Any treatment                  | 69 (54.8)              | 77 (61.1)                  | 146 (57.9)           |
| Non-sedative H1-AH             | 53 (42.1)              | 51 (40.5)                  | 104 (41.3)           |
| Sedative H1-AH                 | **12 (9.5)**           | **25 (19.8)**              | 37 (14.7)            |
| Medication                  | Year 1 | Year 2 | Year 3 |
|----------------------------|--------|--------|--------|
| **Ciclosporin**             | 15 (11.9) | 11 (8.7) | 26 (10.3) |
| **Corticosteroid**          | 13 (10.3) | 12 (9.5) | 25 (9.9) |
| **Montelukast**             | 10 (7.9) | 12 (9.5) | 22 (8.7) |
| **Omalizumab**              | 5 (4.0)  | 0      | 5 (2.0)  |
| **Other**                   | 26 (20.6) | 28 (22.2) | 54 (21.4) |

**Comorbidities, n (%)**

| Comorbidity                     | Year 1 | Year 2 | Year 3 |
|---------------------------------|--------|--------|--------|
| **Depression/anxiety**          | 32 (25.4) | 30 (23.8) | 62 (24.6) |
| **Asthma**                      | 39 (31.0) | 21 (16.7) | 60 (23.8) |
| **Allergic rhinitis**           | 25 (19.8) | 7 (5.6)  | 32 (12.7) |
| **Hypertension**                | 15 (11.9) | 11 (8.7) | 26 (10.3) |
| **Other type of eczema**        | 20 (15.9) | 4 (3.2)  | 24 (9.5)  |
| **Atopic dermatitis**           | 11 (8.7) | 7 (5.6)  | 18 (7.1) |
| **Obesity**                     | 13 (10.3) | 3 (2.4)  | 16 (6.3) |
| **Food allergy**                | 10 (7.9) | 1 (0.8)  | 11 (4.4) |
| **Type 1 diabetes**             | 2 (1.6)  | 1 (0.8)  | 3 (1.2)  |
| **Vitiligo**                    | 0       | 3 (2.4)  | 3 (1.2)  |
| **Hashimoto thyroiditis**       | 2 (1.6)  | 0       | 2 (0.8)  |
| **Other psychosomatic disease** | 0       | 1 (0.8)  | 1 (0.4)  |
| **Lupus erythematosus**         | 0       | 0       | 0       |
| **Hypertriglyceridaemia**       | 0       | 0       | 0       |
| **Other comorbidities**         | 68 (54.0) | 58 (46.0) | 126 (50.0) |
| Category                                                      | Group 1 | Group 2 | Group 3 |
|---------------------------------------------------------------|---------|---------|---------|
| Current wheals or wheals during the last 6 months, n (%)     | 97 (78.2) | 99 (80.5) | 196 (79.4)* |
| Wheals present for >24 hours                                  | 36 (38.3) | 41 (43.2) | 77 (40.7)† |
| Biopsy performed to rule out vasculitis                      | 9 (9.5) | 11 (11.3) | 20 (10.4)‡ |
| Angioedema during the last 6 months, n (%)                   | 83 (66.9) | 55 (44.7) | 138 (55.9)* |
| Wheals present for >24 hours                                  | 36 (38.3) | 41 (43.2) | 77 (40.7)† |
| Biopsy performed to rule out vasculitis                      | 9 (9.5) | 11 (11.3) | 20 (10.4)‡ |
| Angioedema in relation to urticaria                           | 68 (82.9) | 52 (96.3) | 120 (88.2)§ |
| Angioedema in relation to medical treatment                  | 6 (7.3) | 7 (13.0) | 13 (9.6)§ |
| Hereditary angioedema                                         | 2 (2.4) | 1 (1.9) | 3 (2.2)§ |
| Based on an acquired C1 esterase inhibitor deficiency         | 0 | 0 | 0§ |
| Other common underlying cause                                 | 10 (12.2) | 5 (9.3) | 15 (11.0)§ |
| ACE inhibitors during the last 12 months                      | 1 (1.2) | 5 (9.4) | 6 (4.5)¶ |
| Average intensity of angioedema, n (%)                       |         |         |         |
| Negligible                                                    | 0 | 0 | 0§ |
| Mild                                                          | 19 (23.5) | 11 (21.6) | 30 (22.7)§ |
| Moderate                                                      | 33 (40.7) | 33 (64.7) | 66 (50.0)§ |
| Severe                                                        | 29 (35.8) | 7 (13.7) | 36 (27.3)§ |
| Average duration of angioedema (hours), mean (SD)            | 39.2 (44.9) | 71.5 (130.2) | 51.2 (87.7)** |

ACE, angiotensin-converting enzyme; ClndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; H1-AH, H1-antihistamine; SD, standard deviation. *Based on n=247 (five patients missing data); †Based on n=189 (seven patients missing data); ‡Based on n=192 (four patients missing data); §Based on n=136 (two patients missing data); ¶Based on n=134 (four patients missing data).
patients missing data); *Based on n=132 (six patients missing data); **Based on n=97 (41 patients missing data).

**Bold values** indicate p<0.05, for comparison between patients enrolled in allergy versus dermatology centres.
|                           | Baseline (Visit 1) | Year 1 (Visit 5) | Year 2 (Visit 9) |
|---------------------------|-------------------|-----------------|-----------------|
|                           | N                 | N               | N               |
| UAS7, mean (SD)           | 161 (18.4 (13.2)  | 74 (13.4 (12.3)  | 39 (11.3 (10.7)  |
| VAS, mean (SD)            | 241 (6.6 (3.1)    | 78 (8.1 (2.1)    | 36 (7.8 (2.6)    |
| WPAI score, mean (SD)     | 140 (28.8 (27.4)  | 49 (15.1 (20.9)  | 26 (11.5 (17.7)  |
| EQ-5D score, mean (SD)    | 244 (0.66 (0.36)  | 86 (0.73 (0.31)  | 51 (0.78 (0.26)  |
| Total activity impairment, mean (SD) | 238 (34.1 (31.2)  | 80 (18.6 (25.9)  | 47 (14.7 (22.2)  |
| DLQI score, mean (SD)     | 237 (9.5 (8.0)    | 87 (6.1 (7.0)    | 48 (5.0 (6.3)    |
| Effect on patient’s life, n (%) | 237 (237)      | 87 (87)         | 48 (48)         |
| No effect at all (0–1)    | 47 (19.8)         | 26 (29.9)       | 22 (45.8)       |
| Little effect (2–5)       | 46 (19.4)         | 26 (29.9)       | 10 (20.8)       |
| Effect Size               | Group 1 | Group 2 | Group 3 |
|--------------------------|---------|---------|---------|
| Moderate effect (6–10)   | 45 (19.0) | 20 (23.0) | 8 (16.7) |
| Large effect (11–20)     | 73 (30.8) | 10 (11.5) | 6 (12.5) |
| Extremely large effect (21–30) | 26 (11.0) | 5 (5.7) | 2 (4.2) |

| Sick leave, n (%)        | 252     | 3 (1.2) | 92      | 5 (5.4) | 51      | 1 (2.0) |
|--------------------------|---------|---------|---------|---------|---------|---------|
| Duration of sick leave (weeks), mean (SD) | 70      | 17.5 (61.9) | 4       | 1.2 (1.9) | 1       | 0.6 (–) |
| Duration of sick leave due to angioedema (weeks), mean (SD) | 30      | 6.6 (18.9) | 1       | 0.9 (–)   | –       | –       |

DLQI, Dermatology Life Quality Index; EQ-5D, European Quality of Life – 5 Dimensions; SD, standard deviation; UAS7, Urticaria Activity Score over 7 days; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment.
| n (%) | Baseline (Visit 1)* | Year 1 (Visit 5)† | Year 2 (Visit 9)‡ |
|-------|---------------------|-------------------|-------------------|
| Visit to an emergency physician or A&E department | 66 (33.8) | 2 (3.8) | 2 (7.4) |
| Hospitalisation | 24 (12.3) | 2 (3.8) | 1 (3.7) |
| Visit to a specialised urticaria centre | 49 (25.1) | 7 (13.2) | 2 (7.4) |
| Visit to a GP/family physician | 164 (84.1) | 27 (50.9) | 12 (44.4) |
| Visit to an additional dermatologist/allergist | 80 (41.0) | 6 (11.3) | 1 (3.7) |
| Visit to an ENT specialist | 6 (3.1) | 3 (5.7) | 0 |
| Visit to a dentist | 56 (28.7) | 33 (62.3) | 16 (59.3) |
| Visit to a pharmacy | 53 (27.2) | 7 (13.2) | 3 (11.1) |
| Visit to an alternative practitioner | 14 (7.2) | 2 (3.8) | 3 (11.1) |
| Use of other resources | – | 7 (13.2) | 7 (25.9) |

A&E, accident and emergency; ENT, ear, nose and throat; GP, general practitioner. *Based on n=195 (57 patients missing data); †Based on n=53 (40 patients missing data); ‡Based on n=27 (25 patients missing data).
Figure legend

Figure 1 Study design and patient disposition.

ASST, autologous serum skin test*; DLQI, Dermatology Quality of Life Index; EQ-5D, EuroQoL five-dimensions instrument; UAS7, Urticaria Activity Score over 7 days; VAS, visual analogue scale; WPAI, work productivity and activity impairment.

*Not part of routine clinical practice – only used occasionally.
Visit 1
Baseline

Visit 2
Month 3

Visit 3
Month 6

Visit 4
Month 9

Visit 5
Month 12

Visit 6
Month 15

Visit 7
Month 18

Visit 8
Month 21

Visit 9
Month 24

N=252
N=166
N=119
N=112
N=93
N=72
N=64
N=57
N=52

Figure 1

- Demographic
- Vital signs
- Drug therapy
- VAS
- Angioedema episodes
- Wheals
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI

- Drug therapy
- VAS
- Angioedema episodes
- Healthcare use
- Comorbidities
- ASST
- DLQI
- UAS7
- EQ-5D
- WPAI